

# Development and Validation of a Diagnostic Prediction Rule for Osteopenia

Thammabhorn Janwittayanuchit<sup>1</sup>

Naritsaret Kaewboonlert<sup>2,\*</sup>

Pornthep Tangkanjanavelukul<sup>2</sup>

Kitirat Phattaramarut<sup>2</sup>

Pattama Thongdee<sup>2</sup>

1 Suranaree University of Technology Hospital, Nakhon Ratchasima 30000, Thailand

2 Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand

\* Corresponding author: School of Surgery, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand. Tel: +66 4422 3956, E-mail: [naritcvt@gmail.com](mailto:naritcvt@gmail.com)

## 27 **Abstract**

### 28 **Objectives**

29 To triage patients with a high likelihood of osteopenia before referring them for a standard bone  
30 mass density test for diagnosis.

### 31 **Introduction**

32 Osteopenia defined by low bone mineral density, is a precursor for osteoporosis and is primarily  
33 associated with aging-linked natural bone loss in adulthood. The model and findings can be  
34 used to adopt an inclusive screening and swift treatment model that can work in most settings  
35 where resources are limited.

### 36 **Methods**

37 We developed a diagnostic prediction rule based on clinical characteristics. A retrospective  
38 cohort of 798 patients who were going to be diagnosed with osteopenia or osteoporosis, within  
39 January-September 2022. The multivariable logistic regression to assess potential predictors.  
40 The logistic coefficients were transformed as a risk-based scoring system. The internally  
41 validation was performed using a bootstrapping procedure.

### 42 **Results**

43 The model initially included seven predictors: sex, age, height, weight, body mass index,  
44 diabetes mellitus, and estimated glomerular filtration rate. However, after using backward  
45 elimination for model reduction, only three predictors—sex, age, and weight—were retained in  
46 the final model. The discrimination performance was assessed with the area under the receiver  
47 operating characteristic curve (AuROC); it was 0.779 (95%CI 0.74-0.82), and the calibration plot

48 showed good calibration. For internal validation, bootstrap resampling was utilized, yielding an  
49 AuROC of 0.768 (95% CI 0.73-0.81), indicating robust performance of the model.

## 50 **Conclusions**

51 This study developed and internally validated the Osteopenia Simple Scoring System. This  
52 clinical risk score could be one of the important tools for diagnosing osteopenia and allocating  
53 resources in resource-limited settings.

54

## 55 **Keywords**

56 Osteopenia, Osteoporosis, Risk prediction, Diagnostic prediction rule, Clinical prediction

57

## 58 **Introduction**

59 Osteopenia is a decrease in bone mineral density (BMD) below normal values for their  
60 ages, is the initial stage of bone loss, which may progress to a more severe condition i.e.  
61 osteoporosis. However, that doesn't always lead to osteoporosis depending on many factors.  
62 The primary cause of osteopenia is the natural bone loss that occurs gradually during  
63 adulthood. Secondary causes supposed to accelerate bone loss include lifestyle factors[1] such  
64 as smoking, certain underlying diseases, steroid usage, early menopausal woman, rheumatoid  
65 arthritis, and some medications as well. Osteopenia is often a precursor to osteoporosis, which  
66 are now diagnosed by measuring bone mineral density using dual energy X-ray absorptiometry  
67 bone scans.[2] The osteopenia, as defined by the World Health Organization (WHO) is a t-score  
68 between -1 to -2.5, while values less than -2.5 are diagnostic for osteoporosis.[3, 4] Osteopenia

69 is not considered a disease while osteoporosis is. In the other hand, osteopenia is considered a  
70 marker for risk of fractures.[5]

71 The potential predictors of bone mass density in patients with fractures treated in  
72 hospitals were found that factors such as age, sex, smoking, history of adult wrist fractures,  
73 spinal deformities[6, 7], history of adult hip fractures, and osteoarthritis of the spine[8]  
74 significantly differed statistically between groups with normal bone mass density and those with  
75 bone mass density below -1 standard deviation. Low body mass index, low vitamin D level[9]  
76 and diabetes[10, 11], chronic kidney disease[12] are also associated with osteoporosis.

77 There has been increasing attention to the clinical predictive models of diagnostic  
78 screening models for the prediction of fracture risk in patients diagnosed with osteoporosis.[13-  
79 16] Clinical predictive models are commonly used in clinics for the purpose of disease  
80 diagnosis, outcome prediction, and evaluation of the clinical response.[17, 18] We used  
81 multivariable logistic regression to develop predictive models for possible use in the facilitation  
82 of early treatment and screening for osteopenia.

83 In countries with limited resources, access to a test for bone mass density would be far-  
84 fetched. This research aims to help triage patients at high risk of having osteopenia before they  
85 are referred for a standard BMD test for diagnosis. This work could be extended to programs  
86 aimed to osteopenia or osteoporosis screening in the community.

87

88

89

90

## 91 **Methods**

## 92 **Study design and setting**

93 This diagnostic prediction research, utilizing a retrospective cohort design, was  
94 conducted at Suranaree University of Technology Hospital in Nakhon Ratchasima, located in the  
95 lower northeastern region of Thailand. Our university hospital conducts more than 2,000 bone  
96 mass density tests annually.

97 This study retrospectively collected demographic and laboratory data from the electronic  
98 medical records of Suranaree University Technology Hospital. The data included age, weight,  
99 height, body mass index, smoking status, early menopause, rheumatoid arthritis, diabetes  
100 mellitus, chronic kidney disease, serum creatinine levels, and estimated glomerular filtration  
101 rates. Patient data were accessed for research purposes between April 4th and 12th 2024.  
102 Patients who visited the hospital from January to September 2022 and were intended to be  
103 diagnosed with osteopenia or osteoporosis were assessed for eligibility. Patients with a previous  
104 diagnosis of osteopenia or osteoporosis were excluded from the study.

105

## 106 **Confirmation of cases**

107 All patients included in this study underwent a BMD test on a single machine at the  
108 hospital's checkup center. In this study, osteopenia is defined as a T-score of less than -1, and  
109 osteoporosis is defined as a T-score of less than -2.5.

110

## 111 **Statistical analysis and sample size calculations**

112 Continuous variables were assessed for normality and presented as means and  
113 standard deviations if normally distributed, or medians and interquartile ranges if not. Mean

114 differences of the variables between the two groups were compared by using an independent t-  
115 test, or rank-sum test based on the distribution of the data. Categorical data were expressed as  
116 frequencies and percentages of the total in each group and compared between groups using  
117 either the exact probability test or chi-square test where applicable. We assessed diagnostic  
118 performance and potential prediction by univariable logistic regression, using crude odds ratios  
119 (OR) and their corresponding area under the receiver operating characteristic curves (AuROC).  
120 Statistically significant two-sided p-values less than 0.05 were considered in applicable cases.  
121 All analyses were done using Stata statistical software version 17. In the development of clinical  
122 prediction rules based on methods described by Riley et al.[19], it was estimated that the  
123 minimum sample size for a multivariable prediction model with a binary outcome was required.  
124 This was estimated from a model c-statistic of 0.8, six candidate predictors, and an assumed  
125 prevalence of osteopenia from a preliminary study, standing at 46%, to get the minimum sample  
126 size of 382 cases with 176 events.

127

## 128 **Model development and validation**

129 All potential predictor variables necessary for diagnostic prediction of osteopenia in our  
130 routine practice were extracted from the hospital's electronic medical records. These included  
131 age, sex, height, weight, smoking status, serum creatinine levels, diabetes mellitus (with or  
132 without insulin use), hypertension, early menopause, chronic kidney disease, steroid use, and  
133 rheumatoid arthritis.

134 We identified potential predictors based on prior knowledge; about the biological  
135 process, a review of the literature, and available prediction models. Subsequently, the  
136 exploratory analysis of significant predictors was done using a univariable logistic regression.  
137 We assessed the significance of the predictors through the diagnostic odds ratio and the

138 corresponding p-value. Additionally, we assessed the area under the receiver operating  
139 characteristic curve (AuROC) for each univariable logistic model. Any predictor variable showing  
140 an odds ratio >1.00, significant p-value of <0.05, and higher AuROC than others was included in  
141 the model. Continuous potential variables were categorized into ordinal following the preceding  
142 model and review of literature. Therefore, in this respect, understanding the nature of the  
143 relationship between the dependent variable and the outcome to determines the cut-off point.

144 The model to be used for the study is derived from the multivariable logistic regression  
145 with a binary outcome. The factors that not contributing to the outcome were removed using the  
146 backward elimination method. A total of four predictors got pruned from the model: height, body  
147 mass index, diabetes mellitus, and estimated glomerular filtration rate. Diagnostic performance  
148 of the developed model was assessed using the reduced multivariable model by means of  
149 calibration and discrimination. Calibration was assessed by the Hosmer-Lemeshow goodness-  
150 of-fit test, and a plot was applied to show both the model-estimated disease probabilities and  
151 observed disease data. The discriminative ability of the model was graphically tested through a  
152 distributional plot. It was reported with the area under the curve of the receiver operating  
153 characteristic. The internal validation was conducted using the bootstrapping procedure of 1000  
154 replications.

155

156

157

## 158 **Simplified score derivation**

159 Each predictor in the multivariable model was assigned a specific score based on the  
160 logistic regression coefficients. The coefficient of each predictor was divided by the smallest

161 coefficient and then rounded up to the nearest whole number. Utilizing a population-analogue  
162 approach, the positive predictive value (PPV) was calculated to demonstrate the predictive  
163 performance. Calibration and discrimination measurements were also conducted using the  
164 score-based multivariable logistic model.

165

## 166 **Ethical considerations**

167 This research was conducted based on ethical standards of clinical research. According  
168 to the Helsinki Declaration and began its activity only after it received approval and permission  
169 from the Institutional Review Board of Suranaree University of Technology regarding the review  
170 of the research protocol. Retrospective data were extracted through data record forms. The  
171 patients were treated by the routine hospital staff and were not affected by any research  
172 protocols, the informed consent was waived. The study adhered to the reporting guidelines  
173 outlined in the Transparent Reporting of a multivariable prediction model for Individual  
174 Prognosis Or Diagnosis (TRIPOD) statement. The study protocol received approval from the  
175 Institutional Review Board of Suranaree University of Technology, with approval number COA  
176 No.32/2567.

177

178

179

## 180 **Results**

### 181 **Participants**



182 A total of 798 participants were evaluated for osteopenia at the Suranaree University of  
183 Technology check-up center from January to September 2022. After excluding 242 patients  
184 previously diagnosed with osteopenia or osteoporosis, the remaining 556 patients were divided  
185 into two groups: 230 in the osteopenia group and 326 in the non-osteopenia group. The  
186 prevalence of osteopenia and osteoporosis was 41.4% and 5.4%, respectively. Of these, 198  
187 patients in the osteopenia group and 188 in the non-osteopenia group were female. The mean  
188 age for the osteopenia group was  $65.07 \pm 10.34$  years, compared to  $59.03 \pm 9.14$  years for the  
189 non-osteopenia group. The average weight was  $57.40 \pm 9.58$  kg for osteopenia cases and  
190  $57.40 \pm 12.71$  kg for non-osteopenia cases. Average heights were  $155.22 \pm 7.50$  cm for the  
191 osteopenia group and  $160.53 \pm 8.00$  cm for the non-osteopenia group. The mean BMI was  
192  $24.68 \pm 14.44$  kg/m<sup>2</sup> for osteopenia cases and  $25.64 \pm 4.02$  kg/m<sup>2</sup> for non-osteopenia cases  
193 (Table 1). There were significant differences in groups in terms of female gender, age, weight,  
194 height, BMI, and current underlying diseases, including diabetes mellitus, as well as in  
195 laboratory factors such as estimated glomerular filtration rate (eGFR) ( $p < 0.001$ ). There were  
196 no significant differences in the serum creatinine, early menopause, rheumatoid arthritis, and  
197 smoking status.

198

199

200

201

## 202 **Model development and internal validation**

203 The following continuous variables were converted to ordinal variables: eGFR, body  
204 mass index, weight, age, and height. The cut points were determined based on information

205 gathered from the literature and prior models. The model was developed using multivariable  
206 logistic regression, which demonstrated the relevant characteristics included in the regression  
207 for predicting osteopenia were female gender, age, height, weight, BMI, diabetes mellitus, and  
208 eGFR. These factors remained significant in the multivariable logistic regression analysis and  
209 were integrated into the full risk prediction model (Table 2).

210 The reduced model employed a backward elimination strategy. Multivariable logistic  
211 regression indicated that female gender, age, and weight, which were included in the final  
212 model, were found to be statistically significant. The scoring ranged from 1 to a maximum of 5  
213 points, accumulating to a total of 13 points, summing up to 133. Ages over 70 years were  
214 assigned the highest scores (Table 3).

215 The calibration plot of the estimated risk of osteopenia compared to the actual risk  
216 showed acceptable calibration, with observed probabilities closely matching the expected  
217 probabilities and exhibiting minimum variation from the ideal (Figure 2). The Hosmer-Lemeshow  
218 goodness-of-fit statistic yielded a non-significant result for the outcome ( $p = 0.614$ ), suggesting  
219 that the statistical fitness of the model was satisfactory, given that a p-value larger than 0.1 was  
220 regarded indicative of a good fit. Area under the receiver operating characteristic curve  
221 (AuROC) was 0.7792 (95% CI 0.74-0.82), showing a good performance in model discrimination  
222 (Figure 3).

223 The process of internal validation was conducted by utilizing a bootstrap resampling  
224 technique with 1000 repeats. Following the adjustment for optimism in discrimination, the  
225 bootstrap analysis produced an area under the receiver operating characteristic curve (AuROC)  
226 of 0.768 (95% CI 0.73-0.81), indicates a good ability and a significant level of agreement  
227 between the estimated and observed probabilities of risk (Supplementary material).

228

## 229 **Simple score cut point identification**

230 A very high sensitivity of 94.8% (95% CI 91.1-97.3) was observed at a cut point of  $\geq 4$ ,  
231 while the specificity was 28.5% (95% CI 23.7-33.8). At a score of  $\geq 10$ , the specificity was high at  
232 91.7% (95% CI 88.2-94.5), but the sensitivity was lower at 44.3% (95% CI 37.8-51.0). The best  
233 cut point was determined by achieving a balance between sensitivity and specificity. For a score  
234 of 6 or above, the sensitivity was 82.2% (95% CI 76.6-86.9), and the specificity was 55.2%  
235 (95% CI 49.6-60.7), with a likelihood ratio of positive result of 1.83 (95% CI 1.60-2.10). The  
236 positive predictive value was 56.4% (95% CI 50.9-61.8), whereas the negative predictive value  
237 was 81.4% (95% CI 75.7-86.3) (Table 4).

238

## 239 **Clinical utility**

240 In the context of triaging patients for osteopenia, the newly developed diagnostic  
241 prediction rule was applied. 32.37% (180 patients out of 556) were true negatives, this model  
242 can reduce the unnecessary BMD tests. Among the 211 patients who scored negatively (simple  
243 score below 6), 41 patients (18.55%) were false negatives for osteopenia, and only 2 patients  
244 (0.36% of all patients) were diagnosed with osteoporosis. On the other hand, among those with  
245 a positive score test (simple score above 6), 146 patients had normal BMD and were  
246 recommended for follow-up, while 189 patients were confirmed to have osteopenia and received  
247 medical treatment according to the treatment guidelines.

## 248 **Discussion**

249 Despite the limitations, the current study managed to establish a diagnostic rule for  
250 predicting patients with osteopenia, which could strengthen an early diagnosis and the  
251 treatment of patients in osteopenia. This finding is highly relevant because our hospital faces a

252 significant burden of bone density testing and a high prevalence of osteopenia. Moreover, the  
253 application of a predictive diagnosis logistic regression model, as conducted in the current  
254 study, also supports the efforts of other studies to implement more predictive analytics in clinical  
255 settings[20].

256 Our results emphasize the importance of a multi-factor approach in novel predictive  
257 model formulation. Specifically, our model uses the same age, sex, and weight as the known  
258 risk factors, established to predict osteopenia and osteoporosis, proven to be significant in other  
259 studies.[21] Similarly, the use of backward elimination for the purpose of precise identification of  
260 the factors allowed reducing the insignificant height and BMI from the model, as these variables  
261 have negligible impact on the model's predictability of outcomes in our patients.[22]

262 The calibration and discrimination results of our model are satisfactory and being  
263 confirmed. The results of the Hosmer-Lemeshow test and AuROC testify to the model's effective  
264 prediction of true osteopenia cases. This is confirmed by the literature on the appropriateness of  
265 calculating these metrics to check how well a diagnostic tool performs in clinical epidemiology  
266 and diagnostics.[23]

267 Furthermore, the use of this model demonstrated its significant clinical use. The  
268 prioritization of resources based on a simple score, which identifies high and low-risk patients,  
269 may also lower the risk of untreated osteopenia transitioning to osteoporosis and adhere to  
270 WHO, who suggests that more tests should be conducted on populations at higher risks.[24, 25]

271 Although the FRAX score is currently used in predicting the 10-year probability of hip  
272 fracture[26, 27], a study by Teeratakulpisarn et al[28]. reports that even though there is  
273 concordance between the 10-year probability of hip fractures for FRAX scores with and without  
274 BMD, this concordance declines in elderly and osteoporotic participants, and in those with

275 FRAX scores without BMD. Therefore, to achieve higher accuracy, it is advisable to undergo  
276 BMD testing.

277 In 2001, Koh LK et al.[29] designed a simple tool to categorize postmenopausal Asian  
278 women (OSTA score). They utilized a questionnaire to identify those in the cohort with  
279 osteoporosis, defined as BMD T-scores  $\leq -2.5$  and use multivariable logistic regression analysis.  
280 The tool had a good performance with an area under the ROC curve of 0.79. Subsequently, it  
281 showed sensitivity of 91%, specificity of 45%, among others.[29] Additionally, upon a validation  
282 in Thai population, OSTA score presented sensitivity of 51.7% and specificity of 77.4% with a  
283 false negative rate of ~20%.[30-33] The OSTA risk classification system showed that high and  
284 medium-risk patients were significantly more likely to sustain injuries in falls and have different  
285 femoral bone fractures patterns compared to low-risk patients. Machine learning models  
286 particularly artificial neural networks offer another opportunity to predict low BMD. Comparison  
287 of both ANN models to logistic regression models to predict low BMD had no significantly  
288 different in performance for either the femoral neck or lumbar spine.[34] Although the OSTA  
289 score performs well within the Thai population and particularly among postmenopausal women,  
290 however, it can be limited use to the general population.

291 Our model's stability and reliability were internal validation via bootstrapping, process  
292 accounting for the potential optimism that can compromise prediction models developed in  
293 narrow or specific populations. All of these methods make our research more reliable and can  
294 be used to apply to similar settings with limited health care resources.

295 The study also has its limitations. In particular, the specificity of the model at some cut  
296 points was insufficient for real-life applications, resulting in overdiagnosis and overtreatment.  
297 This compromise between sensitivity and specificity is common in the development of  
298 diagnostic instruments, and it needs to be adjusted depending on the costs and risks of the

299 disease. For future research, it is possible not only to include new, more prognostic factors but  
300 also to progress statistical instruments, such as machine learning. Further external validation is  
301 also required before adopting this model in other settings.

302

## 303 **Conclusion**

304 The development of a diagnostic prediction rule for osteopenia in a resource-limited  
305 context is a major progress in the field of bone health management. This instrument is likely to  
306 enhance patient prognosis and maximize the use of available healthcare resources by detecting  
307 and offering timely therapeutic treatment to those at risk.

308

## 309 **Acknowledgement**

310 This paper was supported by Suranaree University of Technology.

311

## 312 **Funding**

313 None

## 314 **Conflict of interest**

315 None

316

## 317 **Author contribution statement**

318 NK and TJ contributed to all parts of the research. PT, KP, and PT focused on discussing,  
319 reviewing, and editing the manuscript.

320

## 321 **Figure legends**

322 **Figure 1:** Study flow.

323 **Figure 2:** Calibration plot for model predicted risk for osteopenia versus actual risk.

324 **Figure 3:** Discrimination performance of the newly developed model, using clinical  
325 characteristics to classify patients with normal and low bone mass density.

326 **Figure 4:** Clinical utility.

327

328

329

330

331

## 332 **Tables**

333 **Table 1:** Baseline patient characteristics, underlying diseases, and laboratory investigations of  
334 the derivation cohort, along with a comparison of osteopenia cases and normal bone mineral  
335 density tests (n = 556).

Patient characteristics	Osteopenia cases (n = 230)		Non-osteopenia cases (n = 326)		Univariable OR (95%CI)	p- value	AuROC
	n	(%)	n	(%)			
Female gender	198	(86.09)	188	(57.67)	4.54 (2.94-	<	0.64 (0.61-0.68)

					7.00)	0.001	
Age, years (mean ± SD)	65.07	± 10.34	59.03	± 9.14	1.07 (1.05-1.09)	< 0.001	0.68 (0.64-0.73)
Weight, kg (mean ± SD)	57.40	± 9.58	66.30	± 12.71	0.93 (0.91-0.95)	< 0.001	0.29 (0.25-0.34)
Height, cm (mean ± SD)	155.22	± 7.50	160.53	± 8.03	0.92 (0.89-0.94)	< 0.001	0.32 (0.28-0.37)
BMI, km/m <sup>2</sup> (mean ± SD)	24.68	± 14.44	25.64	± 4.02	0.88 (0.84-0.93)	< 0.001	0.37 (0.33-0.42)
Current smoking	1	(0.43)	5	(1.54)	0.28 (0.03-2.40)	0.245	0.49 (0.49-0.50)
Early menopause	5	(2.17)	10	(3.09)	0.70 (0.24-2.07)	0.516	0.50 (0.48-0.51)
Rheumatoid arthritis	1	(0.43)	2	(0.62)	0.70 (0.06-7.80)	0.774	0.50 (0.49-0.51)
Diabetes mellitus	15	(6.52)	45	(13.89)	0.43 (0.23-0.80)	0.007	0.46 (0.44-0.49)
Creatinine, g/dL (mean ± SD)	0.87	± 0.72	0.87	± 0.37	1.01 (0.72-1.42)	0.967	0.42 (0.37-0.48)
eGFR, ml/min/1.73 m <sup>2</sup> (mean ± SD)	68.59	± 24.13	83.71	± 25.39	0.97 (0.97-0.98)	< 0.001	0.32 (0.28-0.37)
Chronic kidney disease	25	(10.92)	37	(11.46)	0.95 (0.55-1.62)	0.844	0.50 (0.47-0.52)

336 Abbreviations: eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval

337

338

339

340

341

342 **Table 2:** Full model multivariable logistic regression analysis.

Predictors	Full model		
	mOR	95% CI	P-value
Female	5.33	3.03 - 9.38	0.000
Age, year			
≤ 59	1		
60 – 69	3.59	2.25 - 5.74	< 0.001
≥ 70	6.91	3.62 - 13.20	< 0.001
Height, cm			
≥ 155	1		
< 155	0.97	0.57 - 1.64	0.903
Weight, kg			
≥ 70	1		



60 – 69	1.15	0.61 - 2.17	0.656
50 – 59	1.66	0.72 - 3.82	0.233
≤ 49	1.72	0.54 - 5.54	0.360
Body mass index, kg/m <sup>2</sup>			
≥ 25.0	1		
23.0 – 24.9	1.19	0.64 - 2.22	0.577
18.5 – 22.9	1.71	0.79 - 3.69	0.169
< 18.5	3.94	0.87 - 17.90	0.076
Diabetes mellitus	0.35	0.17 - 0.71	0.004
Estimated GFR			
≥ 60	1		
30 – 59	0.84	0.45 - 1.54	0.565
15 – 29	1.89	0.22 - 16.05	0.558
≤ 14	1	Empty	
Model intercept	.062		

343 Abbreviation: mOR, multivariable odds ratio; BMI, body mass index; GFR, glomerular filtration  
 344 rate

345

346

347

348

349

350

351

352 **Table 3:** Reduced model with logit coefficients.

Predictors	mOR	95% CI	P-value	β Coefficient	Score
Female	4.09	2.51 - 6.68	0.000	1.41	4
Age, year					
≤ 59	1				
60 – 69	3.29	2.13 - 5.08	0.000	1.19	3.5
≥ 70	5.52	3.21 - 9.50	0.000	1.71	5
Weight, kg					
≥ 70	1				
60 – 69	1.40	0.80 - 2.45	0.240	0.34	1
50 – 59	2.60	1.51 - 4.50	0.001	0.96	3
≤ 49	3.96	2.02 - 7.76	0.000	1.38	4
Model intercept	.065				

353 Abbreviation: mOR, multivariable odds ratio; BMI, body mass index

354

355 **Table 4:** Selection of score cut-off point with sensitivity, specificity, LHR+, PPV, NPV, and along  
356 with 95% confidence interval.

Score cut point	Sensitivity (%)	Specificity (%)	LHR+ (%)	PPV (%)	NPV (%)
≥ 4	94.8 (91.1-97.3)	28.5 (23.7-33.8)	1.33 (1.23-1.43)	48.3 (43.6-53.1)	88.6 (80.9-94.0)
≥ 6	82.2 (76.6-86.9)	55.2 (49.6-60.7)	1.83 (1.60-2.10)	56.4 (50.9-61.8)	81.4 (75.7-86.3)
≥ 10	44.3 (37.8-51.0)	91.7 (88.2-94.5)	5.35 (3.63-7.90)	79.1 (71.0-85.7)	70.0 (65.4-74.3)

357 Abbreviation: LHR+, likelihood ratio for positive test; PPV, positive predictive value; NPV,

358 negative predictive value

359

360

361

362

363

364

## 365 References

- 366 1. Rychter AM, Ratajczak AE, Szymczak-Tomczak A, Michalak M, Eder P, Dobrowolska A,  
367 et al. Associations of Lifestyle Factors with Osteopenia and Osteoporosis in Polish Patients with  
368 Inflammatory Bowel Disease. *Nutrients*. 2021;13(6). Epub 2021/06/03. doi:  
369 10.3390/nu13061863. PubMed PMID: 34070791; PubMed Central PMCID: PMC8227497.
- 370 2. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and  
371 treatment of osteoporosis. *Postgrad Med J*. 2007;83(982):509-17. Epub 2007/08/07. doi:  
372 10.1136/pgmj.2007.057505. PubMed PMID: 17675543; PubMed Central PMCID:  
373 PMC8227497.
- 374 3. Sözen T, Özişik L, Başaran N. An overview and management of osteoporosis. *Eur J*  
375 *Rheumatol*. 2017;4(1):46-56. Epub 2017/03/16. doi: 10.5152/eurjrheum.2016.048. PubMed  
376 PMID: 28293453; PubMed Central PMCID: PMC8227497.
- 377 4. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. *Osteoporos Int*. 2005;16  
378 Suppl 2:S3-7. Epub 2004/09/15. doi: 10.1007/s00198-004-1702-6. PubMed PMID: 15365697.

- 379 5. Tran T, Bliuc D, Pham HM, van Geel T, Adachi JD, Berger C, et al. A Risk Assessment  
380 Tool for Predicting Fragility Fractures and Mortality in the Elderly. *J Bone Miner Res.*  
381 2020;35(10):1923-34. Epub 2020/05/28. doi: 10.1002/jbmr.4100. PubMed PMID: 32460361.
- 382 6. Rozental TD, Shah J, Chacko AT, Zurakowski D. Prevalence and predictors of  
383 osteoporosis risk in orthopaedic patients. *Clin Orthop Relat Res.* 2010;468(7):1765-72. Epub  
384 2009/11/17. doi: 10.1007/s11999-009-1162-6. PubMed PMID: 19911243; PubMed Central  
385 PMCID: PMCPMC2881983.
- 386 7. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. *Am J Obstet Gynecol.*  
387 2006;194(2 Suppl):S3-11. Epub 2006/02/02. doi: 10.1016/j.ajog.2005.08.047. PubMed PMID:  
388 16448873.
- 389 8. Grams AE, Rehwald R, Bartsch A, Honold S, Freyschlag CF, Knoflach M, et al.  
390 Correlation between degenerative spine disease and bone marrow density: a retrospective  
391 investigation. *BMC Med Imaging.* 2016;16:17. Epub 2016/02/26. doi: 10.1186/s12880-016-  
392 0123-2. PubMed PMID: 26911278; PubMed Central PMCID: PMCPMC4765052.
- 393 9. Tang G, Feng L, Pei Y, Gu Z, Chen T, Feng Z. Low BMI, blood calcium and vitamin D,  
394 kyphosis time, and outdoor activity time are independent risk factors for osteoporosis in  
395 postmenopausal women. *Front Endocrinol (Lausanne).* 2023;14:1154927. Epub 2023/11/08.  
396 doi: 10.3389/fendo.2023.1154927. PubMed PMID: 37937050; PubMed Central PMCID:  
397 PMCPMC10627178.
- 398 10. Tang Y, Zhang L, Ye D, Zhao A, Liu Y, Zhang M. Causal relationship between Type 1  
399 diabetes and osteoporosis and fracture occurrence: a two-sample Mendelian randomization  
400 analysis. *Osteoporos Int.* 2023;34(6):1111-7. Epub 2023/04/04. doi: 10.1007/s00198-023-06734-  
401 6. PubMed PMID: 37012460.
- 402 11. Ali D, Tencerova M, Figeac F, Kassem M, Jafari A. The pathophysiology of osteoporosis  
403 in obesity and type 2 diabetes in aging women and men: The mechanisms and roles of  
404 increased bone marrow adiposity. *Front Endocrinol (Lausanne).* 2022;13:981487. Epub  
405 2022/10/04. doi: 10.3389/fendo.2022.981487. PubMed PMID: 36187112; PubMed Central  
406 PMCID: PMCPMC9520254.
- 407 12. Hampson G, Elder GJ, Cohen-Solal M, Abrahamsen B. A review and perspective on the  
408 assessment, management and prevention of fragility fractures in patients with osteoporosis and  
409 chronic kidney disease. *Endocrine.* 2021;73(3):509-29. Epub 2021/05/12. doi: 10.1007/s12020-  
410 021-02735-9. PubMed PMID: 33974225; PubMed Central PMCID: PMCPMC8325650.
- 411 13. Tan J, Zhang Z, He Y, Xu X, Yang Y, Xu Q, et al. Development and validation of a risk  
412 prediction model for osteoporosis in elderly patients with type 2 diabetes mellitus: a  
413 retrospective and multicenter study. *BMC Geriatrics.* 2023;23(1):698. doi: 10.1186/s12877-023-  
414 04306-1.
- 415 14. Mauck KF, Cuddihy MT, Atkinson EJ, Melton LJ, 3rd. Use of clinical prediction rules in  
416 detecting osteoporosis in a population-based sample of postmenopausal women. *Arch Intern  
417 Med.* 2005;165(5):530-6. Epub 2005/03/16. doi: 10.1001/archinte.165.5.530. PubMed PMID:  
418 15767529.
- 419 15. Leeyaphan J, Rojjananukulpong K, Intarasompun P, Peerakul Y. Development and  
420 Validation of a New Clinical Diagnostic Screening Model for Osteoporosis in Postmenopausal  
421 Women. *J Bone Metab.* 2023;30(2):179-88. Epub 2023/07/14. doi: 10.11005/jbm.2023.30.2.179.  
422 PubMed PMID: 37449350; PubMed Central PMCID: PMCPMC10346005.
- 423 16. Wang J, Kong C, Pan F, Lu S. Construction and Validation of a Nomogram Clinical  
424 Prediction Model for Predicting Osteoporosis in an Asymptomatic Elderly Population in Beijing. *J  
425 Clin Med.* 2023;12(4). Epub 2023/02/26. doi: 10.3390/jcm12041292. PubMed PMID: 36835828;  
426 PubMed Central PMCID: PMCPMC9967366.
- 427 17. Aibar-Almazán A, Voltés-Martínez A, Castellote-Caballero Y, Afanador-Restrepo DF,  
428 Carcelén-Fraile MDC, López-Ruiz E. Current Status of the Diagnosis and Management of

- 429 Osteoporosis. *Int J Mol Sci.* 2022;23(16). Epub 2022/08/27. doi: 10.3390/ijms23169465.  
430 PubMed PMID: 36012730; PubMed Central PMCID: PMC9408932.
- 431 18. Sun X, Chen Y, Gao Y, Zhang Z, Qin L, Song J, et al. Prediction Models for Osteoporotic  
432 Fractures Risk: A Systematic Review and Critical Appraisal. *Aging Dis.* 2022;13(4):1215-38.  
433 Epub 2022/07/21. doi: 10.14336/ad.2021.1206. PubMed PMID: 35855348; PubMed Central  
434 PMCID: PMC9286920.
- 435 19. Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE, Jr., Moons KG, et al. Minimum sample  
436 size for developing a multivariable prediction model: PART II - binary and time-to-event  
437 outcomes. *Stat Med.* 2019;38(7):1276-96. Epub 2018/10/26. doi: 10.1002/sim.7992. PubMed  
438 PMID: 30357870; PubMed Central PMCID: PMC6519266.
- 439 20. Riley RD, Pate A, Dhiman P, Archer L, Martin GP, Collins GS. Clinical prediction models  
440 and the multiverse of madness. *BMC Med.* 2023;21(1):502. Epub 2023/12/19. doi:  
441 10.1186/s12916-023-03212-y. PubMed PMID: 38110939; PubMed Central PMCID:  
442 PMC9286920.
- 443 21. Poursmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview  
444 on osteoporosis and its risk factors. *Ther Clin Risk Manag.* 2018;14:2029-49. Epub 2018/11/23.  
445 doi: 10.2147/tcrm.S138000. PubMed PMID: 30464484; PubMed Central PMCID:  
446 PMC6225907.
- 447 22. Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical  
448 prediction modelling. *Fam Med Community Health.* 2020;8(1):e000262. Epub 2020/03/10. doi:  
449 10.1136/fmch-2019-000262. PubMed PMID: 32148735; PubMed Central PMCID:  
450 PMC9286920.
- 451 23. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination  
452 and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature. *Jama.*  
453 2017;318(14):1377-84. Epub 2017/10/20. doi: 10.1001/jama.2017.12126. PubMed PMID:  
454 29049590.
- 455 24. Kanis JA. Assessment of fracture risk and its application to screening for  
456 postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. *Osteoporos Int.*  
457 1994;4(6):368-81. Epub 1994/11/01. doi: 10.1007/bf01622200. PubMed PMID: 7696835.
- 458 25. Rubin KH, Holmberg T, Rothmann MJ, Høiberg M, Barkmann R, Gram J, et al. The risk-  
459 stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective population-  
460 based study. Design and baseline characteristics. *Calcif Tissue Int.* 2015;96(2):167-79. Epub  
461 2015/01/13. doi: 10.1007/s00223-014-9950-8. PubMed PMID: 25578146.
- 462 26. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of  
463 osteoporotic fractures according to BMD and diagnostic thresholds. *Osteoporos Int.*  
464 2001;12(12):989-95. Epub 2002/02/16. doi: 10.1007/s001980170006. PubMed PMID:  
465 11846333.
- 466 27. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International  
467 Variations in Hip Fracture Probabilities: Implications for Risk Assessment. *Journal of Bone and*  
468 *Mineral Research.* 2002;17(7):1237-44. doi: <https://doi.org/10.1359/jbmr.2002.17.7.1237>.
- 469 28. Teeratakulpisarn N, Charoensri S, Theerakulpisut D, Pongchaiyakul C. FRAX score with  
470 and without bone mineral density: a comparison and factors affecting the discordance in  
471 osteoporosis treatment in Thais. *Arch Osteoporos.* 2021;16(1):44. Epub 2021/02/27. doi:  
472 10.1007/s11657-021-00911-y. PubMed PMID: 33635451.
- 473 29. Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP, et al. A simple tool to  
474 identify asian women at increased risk of osteoporosis. *Osteoporos Int.* 2001;12(8):699-705.  
475 Epub 2001/10/03. doi: 10.1007/s001980170070. PubMed PMID: 11580084.
- 476 30. Chaovitsaree S, Namwongprom SN, Morakote N, Suntornlimsiri N, Piyamongkol W.  
477 Comparison of osteoporosis self assessment tool for Asian (OSTA) and standard assessment in  
478 Menopause Clinic, Chiang Mai. *J Med Assoc Thai.* 2007;90(3):420-5. Epub 2007/04/13.  
479 PubMed PMID: 17427514.

- 480 31. Geater S, Leelawattana R, Geater A. Validation of the OSTA index for discriminating  
481 between high and low probability of femoral neck and lumbar spine osteoporosis among Thai  
482 postmenopausal women. *J Med Assoc Thai*. 2004;87(11):1286-92. Epub 2005/04/14. PubMed  
483 PMID: 15825701.
- 484 32. Chen CC, Rau CS, Wu SC, Kuo PJ, Chen YC, Hsieh HY, et al. Association of  
485 Osteoporosis Self-Assessment Tool for Asians (OSTA) Score with Clinical Presentation and  
486 Expenditure in Hospitalized Trauma Patients with Femoral Fractures. *Int J Environ Res Public*  
487 *Health*. 2016;13(10). Epub 2016/10/14. doi: 10.3390/ijerph13100995. PubMed PMID:  
488 27735874; PubMed Central PMCID: PMC5086734.
- 489 33. Panichyawat N, Tanmahasamut P. Comparison of OSTA index and KKOS scoring  
490 system for prediction of osteoporosis in postmenopausal women who attended Siriraj  
491 Menopause Clinic. *J Med Assoc Thai*. 2012;95(11):1365-71. Epub 2012/12/21. PubMed PMID:  
492 23252200.
- 493 34. Ongphiphadhanakul B, Rajatanavin R, Chailurkit L, Piaseu N, Teerarungsikul K, Sirisriro  
494 R, et al. Prediction of low bone mineral density in postmenopausal women by artificial neural  
495 network model compared to logistic regression model. *J Med Assoc Thai*. 1997;80(8):508-15.  
496 Epub 1997/08/01. PubMed PMID: 9277083.

497

Patients intended to be diagnosed with osteopenia in the  
Check-up center at Suranaree university of technology.

From January to September 2022

n = 798

Exclude (n = 242)

- Previous diagnosed  
osteopenia or osteoporosis

Patient clinical parameter was recorded.

Bone mineral density (BMD) test


(n = 556)


Osteopenia

(n = 230)

No osteopenia

(n = 326)





Area under ROC curve = 0.7792



Patients intended to be diagnosed with osteopenia.  
(n = 556)

Diagnostic prediction model, Score cut point  $\geq 6$

Negative

Positive

Follow-up (n = 221)

False negative, n = 41 (18.55%)

Bone mineral density test (n = 335)

Negative

Positive

Follow-up (n = 146)

Treatment (n = 189)